Catalyst Pharmaceuticals, Inc.

NasdaqCM:CPRX Stock Report

Market Cap: US$2.5b

Catalyst Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Catalyst Pharmaceuticals has a total shareholder equity of $660.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $772.0M and $111.1M respectively. Catalyst Pharmaceuticals's EBIT is $174.0M making its interest coverage ratio -13.5. It has cash and short-term investments of $442.3M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-13.5x
CashUS$442.33m
EquityUS$660.94m
Total liabilitiesUS$111.07m
Total assetsUS$772.01m

Recent financial health updates

No updates

Recent updates

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27
Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13
Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11
Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Financial Position Analysis

Short Term Liabilities: CPRX's short term assets ($539.0M) exceed its short term liabilities ($105.4M).

Long Term Liabilities: CPRX's short term assets ($539.0M) exceed its long term liabilities ($5.7M).


Debt to Equity History and Analysis

Debt Level: CPRX is debt free.

Reducing Debt: CPRX has not had any debt for past 5 years.

Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies